–(BUSINESS WIRE)–August 26, 2024– Opna Bio announced that it has dosed the first patient with OPN-6602, a potent and selective EP300/CBP bromodomain inhibitor, in a Phase 1 clinical study in ...
Some results have been hidden because they may be inaccessible to you